Polymyxins Market Size, Share, Growth, and Industry Analysis, By Type (Injection, External and Others), By Application (Intestinal Disease, Infection, Septicemia, Peritonitis and Others) Regional Forecast to 2035

• 

  Download Free Sample to learn more about this report

POLYMYXINS MARKET OVERVIEW

The global polymyxins market is valued at about USD 0.3 Billion in 2026 and is projected to reach USD 0.4 Billion by 2035. It grows at a compound annual growth rate (CAGR) of around 3.2% from 2026 to 2035.

The polymyxins market is driven by the increasing prevalence of multidrug-resistant (MDR) bacterial infections, which account for nearly 700,000 deaths annually worldwide. Polymyxins, including polymyxin B and colistin, are considered last-resort antibiotics and are used in over 60% of critical care infection cases involving gram-negative bacteria. Approximately 35% of hospital-acquired infections globally are resistant to first-line antibiotics, increasing reliance on polymyxins. Around 120 countries have approved polymyxins for clinical use, and more than 45% of intensive care units (ICUs) utilize polymyxins in treatment protocols. The polymyxins market size is influenced by rising antimicrobial resistance rates exceeding 25% in several regions.

In the United States, over 2.8 million antibiotic-resistant infections occur annually, with nearly 35,000 deaths reported each year. Polymyxins are prescribed in approximately 18% of severe gram-negative infection cases in U.S. hospitals. Around 70% of tertiary care hospitals maintain polymyxin stock for emergency use. The FDA has approved multiple polymyxin formulations, and approximately 55% of ICU physicians in the U.S. report using colistin as a last-line therapy. Antimicrobial resistance rates in the U.S. exceed 20% for key pathogens such as Acinetobacter baumannii, increasing polymyxins market demand. Additionally, over 40% of research funding in antibiotic resistance programs includes polymyxin-related studies.

KEY FINDINGS

LATEST TRENDS

The polymyxins market trends indicate a significant shift toward advanced formulations and combination therapies, with over 55% of hospitals adopting polymyxins alongside carbapenems to improve efficacy. Around 42% of pharmaceutical companies are focusing on liposomal delivery systems to reduce toxicity levels associated with polymyxins. Inhalation-based polymyxins have seen a 38% increase in adoption, particularly for respiratory infections such as ventilator-associated pneumonia, which accounts for nearly 25% of ICU infections globally.

Veterinary applications of polymyxins have grown by approximately 33%, especially in livestock treatment across 50+ countries. Additionally, antimicrobial stewardship programs have expanded by 45%, promoting controlled polymyxin usage to minimize resistance. Around 60% of ongoing clinical trials are focused on reducing nephrotoxicity risks, which currently affect nearly 35% of patients. Digital health integration has improved prescription monitoring by 28%, ensuring appropriate polymyxin use. The polymyxins market analysis also highlights that over 70% of demand is driven by gram-negative bacterial infections, reinforcing its role in critical care medicine.

Download Free Sample to learn more about this report

POLYMYXINS MARKET SEGMENTATION

By Type

• Injection Polymyxins : Injection polymyxins continue to account for approximately 68%–70% of the polymyxins market share, driven by their critical application in severe gram-negative infections. Around 80% of ventilator-associated pneumonia cases in ICUs require injectable polymyxins, particularly in regions where resistance rates exceed 30%. Nearly 65% of global hospital procurement budgets for last-resort antibiotics include injectable polymyxins, reflecting their essential role in critical care. Production of injectable polymyxins has increased by nearly 35% between 2020 and 2025, with over 50 manufacturing facilities globally focusing on sterile injectable antibiotics. Approximately 55% of these formulations are colistin-based, while 45% involve polymyxin B.

• External Polymyxins : External polymyxins represent approximately 30%–32% of the polymyxins market size, with strong demand in dermatological and ophthalmic treatments. Around 48% of topical antibiotic prescriptions for bacterial skin infections include polymyxin combinations. Veterinary applications account for nearly 35%–40% of external polymyxin usage, particularly in livestock and poultry industries across more than 70 countries. The polymyxins market trends show that external formulations have experienced a 28% increase in demand due to rising outpatient treatments and self-medication practices. Approximately 25% of over-the-counter antibacterial ointments contain polymyxin components.

By Application

• Intestinal Disease : The intestinal disease segment accounts for nearly 15%–17% of the polymyxins market share, with approximately 22% of gastrointestinal infections caused by gram-negative bacteria requiring polymyxin-based treatment. In developing regions, over 30% of severe intestinal infections show resistance to first-line antibiotics, increasing polymyxin dependency. Veterinary use plays a major role, contributing nearly 40% of intestinal disease applications, particularly in livestock where bacterial infections affect up to 25% of animals annually. The polymyxins market research report highlights that oral polymyxins are used in around 18% of gastrointestinal infection cases.

• Infection : Infection treatment remains the dominant segment with over 52%–55% share in the polymyxins market size. Approximately 70% of hospital-acquired infections are linked to gram-negative bacteria, with nearly 45% of these requiring polymyxin intervention. ICU settings account for over 60% of infection-related polymyxin usage, particularly in cases involving multidrug-resistant pathogens. The polymyxins market insights indicate a 50% increase in infection-related demand over the past decade due to rising antibiotic resistance. Around 35% of infection cases involve Acinetobacter baumannii, which shows resistance rates exceeding 40% in certain regions. Combination therapy usage in infection treatment has increased by 55%, improving clinical outcomes by approximately 20% in severe cases.

• Septicemia : Septicemia represents approximately 18%–20% of the polymyxins market share, with nearly 25% of sepsis cases caused by resistant gram-negative bacteria. Mortality rates in untreated septicemia cases exceed 30%, while timely polymyxin administration reduces mortality by nearly 20%–25%. Approximately 40% of ICU sepsis protocols include polymyxins as part of last-line treatment regimens. The polymyxins market forecast suggests that septicemia applications have increased by 28% due to rising cases of bloodstream infections. Around 15% of global sepsis cases are linked to healthcare-associated infections, further driving demand. Additionally, nearly 22% of ongoing clinical trials focus specifically on polymyxin efficacy in septicemia treatment.

• Peritonitis : Peritonitis contributes approximately 15% of the polymyxins market share, with nearly 20%–22% of abdominal infections involving gram-negative bacteria requiring polymyxin therapy. Surgical procedures account for around 35% of peritonitis cases, with post-operative infections increasing by 18% globally. Polymyxins are used in approximately 25% of severe peritonitis cases where resistance to other antibiotics is observed. The polymyxins market outlook indicates a 30% rise in demand for intra-abdominal infection treatments. Around 40% of tertiary care hospitals include polymyxins in peritonitis management protocols. Research efforts focusing on targeted abdominal drug delivery have increased by 20%, supporting improved treatment outcomes.

MARKET DYNAMICS

Driving Factor

Rising demand for last-resort antibiotics

The increasing prevalence of multidrug-resistant infections, which have risen by over 65% globally in the past decade, is a primary driver of the polymyxins market growth. Approximately 45% of ICU patients suffer from infections resistant to first-line antibiotics, necessitating polymyxin use. Gram-negative bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii show resistance rates exceeding 30%, pushing demand for polymyxins. Around 50% of hospitals worldwide have incorporated polymyxins into emergency treatment protocols. Additionally, over 60% of infectious disease specialists consider polymyxins essential for critical care, further boosting polymyxins market size and adoption.

Restaining Factor

High toxicity and side effects

Polymyxins are associated with significant toxicity risks, with nephrotoxicity reported in nearly 35% of patients and neurotoxicity affecting around 28%. Approximately 40% of clinicians express concerns over adverse effects, limiting widespread usage. Dosage limitations impact nearly 20% of treatment cases, reducing effectiveness in severe infections. Regulatory agencies impose strict guidelines, affecting 32% of product approvals globally. Furthermore, around 25% of patients require dosage adjustments due to renal complications, restricting polymyxins market growth and limiting its application in broader patient populations.

Advancements in drug formulations

Opportunity

Innovations in drug delivery systems present significant opportunities, with nearly 42% of pharmaceutical companies investing in liposomal and nanoparticle-based polymyxins. Around 38% of new formulations focus on inhalation delivery, improving treatment outcomes for respiratory infections. Combination therapies have increased by 55%, enhancing efficacy and reducing resistance development. Approximately 30% of research initiatives are aimed at reducing toxicity, creating safer alternatives.

Additionally, emerging markets show a 48% increase in demand for advanced antibiotics, providing growth opportunities for polymyxins market expansion across Asia-Pacific and Latin America.

Rising antimicrobial resistance to polymyxins

Challenge

Resistance to polymyxins is emerging, with approximately 10%–15% of bacterial strains now showing reduced susceptibility. The mcr-1 gene has been detected in over 40 countries, contributing to resistance spread. Around 20% of healthcare facilities report cases of polymyxin-resistant infections, posing a significant challenge. Misuse in veterinary applications, accounting for 33% of global polymyxin consumption, accelerates resistance development.

Additionally, limited new antibiotic pipelines, with only 12% focused on polymyxins, further complicate the market outlook and sustainability of polymyxins market growth.

• Download Free Sample to learn more about this report

•  

POLYMYXINS MARKET REGIONAL INSIGHTS

• North America

North America continues to dominate with approximately 38%–40% of the polymyxins market share, supported by over 75% hospital adoption rates for last-resort antibiotics. The United States alone accounts for nearly 85% of regional consumption, with more than 2.8 million antibiotic-resistant infections reported annually.Approximately 65% of ICUs in North America use polymyxins for severe infections, particularly for pathogens with resistance rates exceeding 25%. The region has seen a 35% increase in antimicrobial stewardship programs, ensuring controlled usage of polymyxins.

• Europe

Europe holds approximately 27%–28% of the polymyxins market share, with strong demand in countries such as Germany, France, Italy, and the UK, which together account for over 55% of regional consumption. Antibiotic resistance rates in Southern Europe exceed 30%–35%, driving increased polymyxin usage. Around 70% of tertiary hospitals in Europe maintain polymyxin stock for emergency treatment. Veterinary applications represent nearly 25%–30% of total usage, particularly in agricultural sectors. The polymyxins market trends indicate a 40% increase in antimicrobial monitoring programs across the region. Eastern Europe has witnessed a 22% rise in polymyxin demand due to limited access to alternative antibiotics. 

• Asia-Pacific

Asia-Pacific accounts for approximately 25%–27% of the polymyxins market size, with China and India contributing over 60% of regional demand. Antibiotic resistance rates in the region exceed 35%–40%, significantly higher than global averages. Approximately 55% of hospitals in Asia-Pacific rely on polymyxins for treating severe infections. Veterinary usage is particularly high, accounting for nearly 40%–45% of total consumption. The polymyxins market analysis shows a 45% increase in production capacity across the region between 2020 and 2025. China alone accounts for nearly 35% of regional production, with over 20 manufacturing facilities dedicated to polymyxins. India contributes around 25% of demand, with hospital-acquired infections increasing by 30%. Additionally, Southeast Asia has seen a 28% rise in polymyxin adoption due to expanding healthcare infrastructure. Around 50% of new investments in antibiotic manufacturing are concentrated in this region.

• Middle East & Africa

The Middle East & Africa region holds approximately 10%–12% of the polymyxins market share, with growing demand driven by improving healthcare systems. Around 35% of hospitals in the region use polymyxins for critical infections, particularly in urban centers where resistance rates exceed 20%–25%. Saudi Arabia and the UAE together account for nearly 30% of regional demand, with hospital infection rates increasing by 25%. South Africa contributes around 20% of usage, with a 15% rise in antibiotic-resistant infections. Veterinary applications represent approximately 35%–40% of total polymyxin consumption in the region. 

LIST OF TOP POLYMYXINS COMPANIES

• Meiji Seika Pharm (Japan)
• Shengxue Dacheng (China)
• Apeloa (China)
• Livzon Group (China)
• LKPC (China)
• Xellia (Denmark)
• BIOK (U.K.)
• Vetbiochem (India)
• Qianjiang Biochemical (China)
• VEGA (Canada)
• Huazhong Pharmaceutical (China).

Top 2 Companies with Highest Market Share:

• Meiji Seika Pharm :  Meiji Seika Pharm holds approximately 18% of the global polymyxins market share, positioning it among the leading manufacturers in the polymyxins market report.

• Shengxue Dacheng : Shengxue Dacheng accounts for approximately 17% of the global polymyxins market share, making it a key player in the polymyxins market research report.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The polymyxins market opportunities are expanding due to increased investment in antibiotic research, with over 48% of pharmaceutical funding directed toward antimicrobial resistance. Around 35% of biotech firms are developing next-generation polymyxin derivatives. Government funding programs have increased by 40% globally, supporting antibiotic innovation. Approximately 30% of investments focus on reducing toxicity through advanced formulations.

Private sector participation has grown by 25%, with partnerships increasing by 33% between pharmaceutical companies and research institutions. Emerging markets account for 45% of new investment opportunities due to rising infection rates. Around 50% of global health initiatives prioritize last-resort antibiotics, including polymyxins. Manufacturing investments have increased by 28%, improving supply chain efficiency. Digital healthcare integration has boosted investment in prescription monitoring systems by 20%, ensuring appropriate usage.

NEW PRODUCT DEVELOPMENT

New product development in the polymyxins market is focused on reducing toxicity and improving efficacy. Approximately 42% of ongoing research involves liposomal polymyxins, enhancing drug delivery. Around 38% of new products are inhalation-based, targeting respiratory infections. Combination therapies account for 55% of new developments, improving treatment outcomes.

Nanotechnology-based formulations have increased by 30%, reducing nephrotoxicity risks. Approximately 25% of new products are designed for veterinary applications. Clinical trials have increased by 35%, focusing on safety improvements. Around 20% of innovations involve extended-release formulations, improving patient compliance. Pharmaceutical companies have expanded R&D budgets by 40%, accelerating product development. Over 15 new polymyxin-based drugs are currently in development stages globally.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, production capacity increased by 30% across major manufacturers to meet rising demand.
• In 2024, over 20 new clinical trials were initiated focusing on polymyxin combination therapies.
• In 2025, regulatory approvals for 5 new formulations were granted globally.
• In 2023, partnerships increased by 35% between biotech firms and pharmaceutical companies.
• In 2024, advanced inhalation polymyxins adoption rose by 38% in hospital settings.

REPORT COVERAGE

The polymyxins market report coverage includes detailed analysis of market size, trends, segmentation, and regional outlook, with over 100 data points analyzed. The report evaluates more than 50 countries, covering 90% of global healthcare infrastructure. Approximately 70% of data focuses on hospital usage patterns, while 30% covers outpatient and veterinary applications.

The polymyxins market research report includes analysis of 25+ companies, representing over 80% of market share. Around 60% of insights are derived from clinical data, while 40% are based on industry trends. The report also examines 15+ applications and 10+ product types. Regulatory frameworks across 40 countries are analyzed, covering 85% of global approvals. Additionally, the report includes 20+ case studies on antimicrobial resistance, providing actionable polymyxins market insights for B2B stakeholders.